Cargando…

Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase

This study has compared the preferential killing of three multidrug-resistant (MDR) KB cell lines, KB-C1, KB-A1 and KB-V1 by two inhibitors of glucosylceramide synthase, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol (PPPP), to the k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nicholson, K M, Quinn, D M, Kellett, G L, Warr, J R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362922/ https://www.ncbi.nlm.nih.gov/pubmed/10507766 http://dx.doi.org/10.1038/sj.bjc.6690711

Ejemplares similares

2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis.
por: Bell, S. E., et al.
Publicado: (1998)

A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis
por: Patwardhan, Gauri A., et al.
Publicado: (2009)

New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression
por: Gupta, Vineet, et al.
Publicado: (2013)

Glucosylceramide synthase maintains influenza virus entry and infection
por: Drews, Kelly, et al.
Publicado: (2020)

Antiviral activity of glucosylceramide synthase inhibitors in alphavirus infection of the central nervous system
por: Avraham, Roy, et al.
Publicado: (2023)

Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer
por: Liu, Jiannan, et al.
Publicado: (2016)

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
por: Stefanovic, Milica, et al.
Publicado: (2016)

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016)

Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus
por: Vitner, Einat B., et al.
Publicado: (2021)

The Glucosylceramide Synthase Inhibitor PDMP Causes Lysosomal Lipid Accumulation and mTOR Inactivation
por: Hartwig, Pia, et al.
Publicado: (2021)

A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
por: Fujii, Takahiro, et al.
Publicado: (2021)

ARF6 Regulates Neuron Differentiation through Glucosylceramide Synthase
por: Li, Lu, et al.
Publicado: (2013)

Glucosylceramide Synthase Is Involved in Development of Invariant Natural Killer T Cells
por: Popovic, Zoran V., et al.
Publicado: (2017)

Role of Intracellular Lipid Logistics in the Preferential Usage of Very Long Chain-Ceramides in Glucosylceramide
por: Yamaji, Toshiyuki, et al.
Publicado: (2016)

Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
por: Ashe, Karen M., et al.
Publicado: (2011)

Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
por: te Vruchte, Danielle, et al.
Publicado: (2022)

Doxorubicin Influences the Expression of Glucosylceramide Synthase in Invasive Ductal Breast Cancer
por: Zhang, Xiaofang, et al.
Publicado: (2012)

A chemical genetic screen reveals that iminosugar inhibitors of plant glucosylceramide synthase inhibit root growth in Arabidopsis and cereals
por: Rugen, Michael D., et al.
Publicado: (2018)

Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase
por: Henriques, Alexandre, et al.
Publicado: (2015)

Control of Glucosylceramide Production and Morphogenesis by the Bar1 Ceramide Synthase in Fusarium graminearum
por: Rittenour, William R., et al.
Publicado: (2011)

Glucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking
por: Andersson, Linda, et al.
Publicado: (2021)

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
por: Baccam, Gabriel C., et al.
Publicado: (2022)

Increased Hepatic Insulin Action in Diet-Induced Obese Mice Following Inhibition of Glucosylceramide Synthase
por: Yew, Nelson S., et al.
Publicado: (2010)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

Convenient and Sensitive Measurement of Lactosylceramide Synthase Activity Using Deuterated Glucosylceramide and Mass Spectrometry
por: Dei Cas, Michele, et al.
Publicado: (2023)

Human Glucosylceramide Synthase at Work as Provided by “In Silico” Molecular Docking, Molecular Dynamics, and Metadynamics
por: Canini, Giorgia, et al.
Publicado: (2023)

Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation
por: El Malki, Khalifa, et al.
Publicado: (2023)

Incorporation of Fluorescence Ceramide-Based HPLC Assay for Rapidly and Efficiently Assessing Glucosylceramide Synthase In Vivo
por: Khiste, Sachin K., et al.
Publicado: (2017)

An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells
por: Chiu, Wei-Hsin, et al.
Publicado: (2015)

Neuronal Expression of Glucosylceramide Synthase in Central Nervous System Regulates Body Weight and Energy Homeostasis
por: Nordström, Viola, et al.
Publicado: (2013)

Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl-2/Bax pathway
por: Li, Jun-Feng, et al.
Publicado: (2017)

CgGCS, Encoding a Glucosylceramide Synthase, Is Required for Growth, Conidiation and Pathogenicity in Colletotrichum gloeosporioides
por: Huang, Yimei, et al.
Publicado: (2019)

Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signaling
por: Liu, Yong-Yu, et al.
Publicado: (2010)

Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
por: Cabrera-Salazar, Mario A., et al.
Publicado: (2012)

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
por: Song, Chang W., et al.
Publicado: (2012)

Glucosylceramide synthase regulates hepatocyte repair after concanavalin A-induced immune-mediated liver injury
por: Gan, Jian, et al.
Publicado: (2021)

Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation
por: Li, Zhiqiang, et al.
Publicado: (2021)

Development of a Label-Free LC-MS/MS-Based Glucosylceramide Synthase Assay and Its Application to Inhibitors Screening for Ceramide-Related Diseases
por: Fu, Zhicheng, et al.
Publicado: (2019)

Horse-Derived Ceramide Accentuates Glucosylceramide Synthase and Ceramide Synthase 3 by Activating PPARβ/δ and/or PPARγ to Stimulate Ceramide Synthesis
por: Igarashi, Tami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kol9o773701ela5vafb1k89cqt